WHAT THE STUDY ACTUALLY SAYSScreening 2,904 proteins in early pregnancy, researchers found low maternal isthmin-2 was the strongest signal for later preeclampsia or fetal growth restriction, validated in two cohorts.
3 min read
EXPLAINERKidney disease is usually silent until it is advanced, and most of it traces to diabetes and high blood pressure. Controlling those two, and getting tested, is the highest-yield protection — not kidney superfoods.
3 min read
ANALYSISA review by the country's Public Health Authority credits enforcement and awareness campaigns for falls in crashes, deaths and injuries from 2013 to 2023 — while naming what still holds the Vision 2030 target back.
3 min read
EXPLAINERHepatitis C is usually silent for years and is the reason for much chronic liver disease. A short course of antiviral pills cures more than 95% of cases, which is what changed the screening advice.
3 min read
EXPLAINERLow fluid intake is a genuine, well-evidenced stone risk factor. Increasing fluid to produce plenty of urine is the single best-supported way to prevent another stone — better established than any diet tweak.
3 min read
WHAT THE STUDY ACTUALLY SAYSObservational studies link higher water intake to healthier kidneys. When a randomised trial coached people with kidney disease to drink more, their filtration fell at the same rate as the control group.
3 min read
EXPLAINERA standing commission estimates that eliminating 14 risk factors could prevent or delay 45% of dementia across a whole population. What that number means for one person is a different and much weaker claim.
4 min read
EXPLAINERSPF measures how much ultraviolet exposure it takes to burn, not how long you can stay outside. The randomised cancer-prevention evidence rests largely on 1,621 adults followed for more than a decade.
5 min read
EXPLAINERA cluster-randomised trial in Guangzhou cut three-year myopia incidence by 9.1 percentage points with 40 extra minutes outdoors a day. The eye's underlying growth barely changed.
5 min read
ANALYSISThe LEAP trial reversed a generation of avoidance advice. A second trial run in the general population missed its primary endpoint, and the distance between those two results is the part usually left out.
5 min read
ANALYSISThe ESC Atlas reports 68 million disability-adjusted life years and more than three million cardiovascular deaths a year, with middle-income countries carrying roughly double the mortality of high-income ones.
4 min read
ANALYSISAn econometric analysis of the 2019 European Health Interview Survey prices smoking-attributable inpatient and daycare hospitalisation across the EU — deliberately excluding every other kind of care.
4 min read
WHAT THE STUDY ACTUALLY SAYSA secondary analysis of 8,376 adolescents built two models to predict who benefits from school-based mindfulness training. Both found a subgroup — and the difference in outcomes was trivial.
3 min read
WHAT THE STUDY ACTUALLY SAYSA survey-based analysis of the European Health Interview Survey puts a price on Europe's obesity-related hospital use, and finds the strongest single association is not with obesity at all.
4 min read
Intimate partner violence has declined by 0.2% a year over two decades. The report also produces the first national and regional estimates of sexual violence by someone other than a partner.
4 min read
THE DRUG DOCKETThe recommendation covers people weighing at least 35 kg and rests on two trials in which lenacapavir cut HIV infections by 100% and 96% against background incidence.
3 min read
WHAT THE STUDY ACTUALLY SAYSAn Australian cohort of 3,044 children found no protective factor held across all ages and outcomes. School safety mattered at age 6-7; belonging mattered at 12-13.
4 min read
ANALYSISA Spanish trial in 4,746 adults compared an energy-reduced Mediterranean diet plus exercise against the same diet eaten freely. Over six years the absolute gap was 12.0% versus 9.5%.
4 min read
The guidelines pair the new injectable with a second, quieter recommendation: use simplified rapid diagnostic testing to start and continue long-acting PrEP, rather than more complex assays.
4 min read
THE DRUG DOCKETLenacapavir is the first HIV pre-exposure prophylaxis given every six months. Two phase 3 trials found zero and two infections in the lenacapavir groups against background rates above 2 per 100 person-years.
4 min read